Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) SEC filings
ADAP SEC filings moved a median of -0.64% by the close. ADAP SEC filings — 10-K, 10-Q, 8-K and the rest — each read against the price at its own news timestamp. Back to the ADAP overview →
60 measured ADAP SEC filing events.
Where these ADAP SEC filings landedvs 57 measured ADAP SEC filing reactions
| Middle 50% of ADAP SEC filing reactions | -6.58% to +3.72% |
|---|---|
| Median reaction (to close) | -0.64% |
| Measured reactions | 57 |
Point-in-time · zero look-ahead
Half of the 57 ADAP SEC filing events with a measured close landed between -6.58% and +3.72%; 47% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 25 Adaptimmune Therapeutics | SEC filing · Form 25 | — | — | |
| Form POS AM Adaptimmune Therapeutics | SEC filing · Form POS | — | — | |
| Form S-8 POS Adaptimmune Therapeutics | SEC filing · Form S-8 | — | — | |
| Form 8-K Adaptimmune Therapeutics For: Oct 15 | SEC filing · Form 8-K | -1.54% | -9.23% | |
| Form 8-K Adaptimmune Therapeutics For: Sep 22 | SEC filing · Form 8-K | +3.56% | -11.05% | |
| Form 8-K Adaptimmune Therapeutics For: Sep 11 | SEC filing · Form 8-K | -3.69% | +2.46% | |
| Form 8-K Adaptimmune Therapeutics For: Sep 06 | SEC filing · Form 8-K | -0.23% | +10.56% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 29 | SEC filing · Form 8-K | -1.00% | -3.67% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 15 | SEC filing · Form 8-K | -4.33% | -20.27% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 14 | SEC filing · Form 8-K | -1.96% | -16.67% | |
| Form 10-Q Adaptimmune Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.77% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 13 | SEC filing · Form 8-K | +0.00% | +0.77% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 07 | SEC filing · Form 8-K | -2.41% | -6.63% | |
| Form 8-K Adaptimmune Therapeutics For: Jul 31 | SEC filing · Form 8-K | -6.95% | -10.43% | |
| Form 8-K Adaptimmune Therapeutics For: Jul 27 | SEC filing · Form 8-K | -6.67% | -33.33% | |
| Form 8-K Adaptimmune Therapeutics For: Jul 16 | SEC filing · Form 8-K | +2.59% | +3.52% | |
| Form 8-K Adaptimmune Therapeutics For: May 29 | SEC filing · Form 8-K | -1.60% | +3.72% | |
| Form 10-Q Adaptimmune Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +1.68% | +8.89% | |
| Form 8-K Adaptimmune Therapeutics For: May 13 | SEC filing · Form 8-K | -7.05% | -17.68% | |
| Form 8-K Adaptimmune Therapeutics For: May 01 | SEC filing · Form 8-K | +0.04% | +3.70% | |
| Form ARS Adaptimmune Therapeutics For: Dec 31 | SEC filing · Form ARS | +3.70% | +2.63% | |
| Form DEF 14A Adaptimmune Therapeutics For: May 29 | SEC filing · Form DEF | -2.61% | -6.58% | |
| Form S-3 Adaptimmune Therapeutics | SEC filing · Form S-3 | +0.64% | -2.46% | |
| Form PRE 14A Adaptimmune Therapeutics For: May 29 | SEC filing · Form PRE | -0.42% | +3.96% | |
| Form 8-K Adaptimmune Therapeutics For: Apr 14 | SEC filing · Form 8-K | -0.42% | +3.96% | |
| Form 10-K Adaptimmune Therapeutics For: Dec 31 | SEC filing · Form 10-K | +1.05% | -11.35% | |
| Form 8-K Adaptimmune Therapeutics For: Mar 24 | SEC filing · Form 8-K | +1.05% | -11.35% | |
| Form 8-K Adaptimmune Therapeutics For: Mar 20 | SEC filing · Form 8-K | -16.28% | -34.88% | |
| Form 8-K Adaptimmune Therapeutics For: Dec 18 | SEC filing · Form 8-K | -0.75% | +0.00% | |
| Form 10-Q Adaptimmune Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -8.03% | -27.01% | |
| Form 8-K Adaptimmune Therapeutics For: Nov 13 | SEC filing · Form 8-K | +0.81% | -6.02% | |
| Form 8-K Adaptimmune Therapeutics For: Nov 01 | SEC filing · Form 8-K | +0.61% | +3.44% | |
| Form 8-K Adaptimmune Therapeutics For: Sep 23 | SEC filing · Form 8-K | +1.57% | +2.21% | |
| Form 10-Q Adaptimmune Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +4.81% | +4.81% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 12 | SEC filing · Form 8-K | +4.81% | +4.81% | |
| Form 8-K Adaptimmune Therapeutics For: Aug 01 | SEC filing · Form 8-K | -8.33% | -11.36% | |
| Form 8-K Adaptimmune Therapeutics For: Jul 16 | SEC filing · Form 8-K | +1.01% | +1.61% | |
| Form 8-K Adaptimmune Therapeutics For: Jun 11 | SEC filing · Form 8-K | +1.91% | -0.95% | |
| Form 8-K Adaptimmune Therapeutics For: May 30 | SEC filing · Form 8-K | -3.02% | -2.59% | |
| Form 10-Q Adaptimmune Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -5.22% | -10.45% | |
| Form 8-K Adaptimmune Therapeutics For: May 14 | SEC filing · Form 8-K | +2.70% | +4.20% | |
| Form 8-K Adaptimmune Therapeutics For: May 15 | SEC filing · Form 8-K | +2.70% | +4.20% | |
| Form 8-K Adaptimmune Therapeutics For: May 14 | SEC filing · Form 8-K | +2.61% | -1.71% | |
| Form ARS Adaptimmune Therapeutics For: Dec 31 | SEC filing · Form ARS | -1.92% | +9.62% | |
| Form 8-K Adaptimmune Therapeutics For: Apr 10 | SEC filing · Form 8-K | -3.33% | -3.33% | |
| Form DEF 14A Adaptimmune Therapeutics For: May 14 | SEC filing · Form DEF | +2.34% | +0.78% | |
| Form PRE 14A Adaptimmune Therapeutics For: May 14 | SEC filing · Form PRE | -1.94% | -5.16% | |
| Form 10-K Adaptimmune Therapeutics For: Dec 31 | SEC filing · Form 10-K | -5.66% | +7.55% | |
| Form 8-K Adaptimmune Therapeutics For: Mar 06 | SEC filing · Form 8-K | -5.66% | +7.55% | |
| Form 8-K Adaptimmune Therapeutics For: Feb 26 | SEC filing · Form 8-K | +1.21% | +3.64% | |
| Form 8-K Adaptimmune Therapeutics For: Feb 16 | SEC filing · Form 8-K | +0.85% | +6.78% | |
| Form 8-K Adaptimmune Therapeutics For: Jan 31 | SEC filing · Form 8-K | +1.94% | -2.91% | |
| Form 8-K Adaptimmune Therapeutics For: Jan 04 | SEC filing · Form 8-K | +6.39% | +6.71% | |
| Form 8-K Adaptimmune Therapeutics For: Dec 06 | SEC filing · Form 8-K | +2.64% | -1.14% | |
| Form S-8 Adaptimmune Therapeutics | SEC filing · Form S-8 | +0.17% | +15.07% | |
| Form 8-K Adaptimmune Therapeutics For: Nov 14 | SEC filing · Form 8-K | -4.46% | -1.63% | |
| Form 10-Q Adaptimmune Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +3.80% | -0.64% | |
| Form 8-K Adaptimmune Therapeutics For: Nov 08 | SEC filing · Form 8-K | +0.00% | -1.30% | |
| Form 8-K Adaptimmune Therapeutics For: Nov 01 | SEC filing · Form 8-K | +1.21% | +1.24% | |
| Form 8-K Adaptimmune Therapeutics For: Oct 31 | SEC filing · Form 8-K | -5.26% | -5.14% |
Keep exploring
More ADAP: earnings → · analyst actions → · ADAP overview →
Other Healthcare names and their SEC filings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Zomedica Corp. Common Shares (ZOM) | 161 | +0.08% | 53% |
| AVITA MEDICAL (AVMXY) | 160 | 0.00% | 46% |
| DURECT Corporation (DRRX) | 159 | +0.03% | 51% |
| Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD) | 159 | -1.80% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its SEC filings — that is what the link opens.